New pill could regrow hair in balding men

NCT ID NCT06972264

First seen Nov 06, 2025 · Last updated May 07, 2026 · Updated 28 times

Summary

This study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take the drug or a placebo daily for about 13 months. The main goal is to see if the drug increases hair count and if participants notice a benefit after 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Site 51

    Austin, Texas, 78759, United States

  • Site 52

    Louisville, Kentucky, 40241, United States

  • Site 53

    Clarksville, Indiana, 47129, United States

  • Site 54

    Ocala, Florida, 34470, United States

  • Site 55

    Plainfield, Indiana, 46168, United States

  • Site 57

    Portland, Oregon, 97210, United States

  • Site 59

    Quincy, Massachusetts, 02169, United States

  • Site 60

    Anderson, South Carolina, 29625, United States

  • Site 61

    Chicago, Illinois, 60611, United States

  • Site 62

    Coral Gables, Florida, 33146, United States

  • Site 63

    Norfolk, Virginia, 23502, United States

  • Site 64

    Manhattan Beach, California, 90266, United States

  • Site 66

    Santa Monica, California, 90404, United States

  • Site 67

    Dallas, Texas, 75230, United States

  • Site 68

    Clinton Township, Michigan, 48038, United States

  • Site 69

    Encino, California, 91436, United States

  • Site 70

    Mill Creek, Washington, 98012, United States

  • Site 71

    Boca Raton, Florida, 33486, United States

  • Site 72

    Cincinnati, Ohio, 45236, United States

  • Site 73

    Birmingham, Alabama, 35209, United States

  • Site 74

    College Station, Texas, 77845, United States

  • Site 75

    New Orleans, Louisiana, 70124, United States

  • Site 76

    Austin, Texas, 78746, United States

  • Site 77

    Phoenix, Arizona, 85006, United States

  • Site 78

    Plano, Texas, 75024, United States

  • Site 79

    Leawood, Kansas, 66211, United States

  • Site 80

    Chestnut Hill, Massachusetts, 02467, United States

  • Site 81

    East Greenwich, Rhode Island, 02818, United States

  • Site 82

    Hickory, North Carolina, 28602, United States

  • Site 83

    Troy, Michigan, 48084, United States

  • Site 84

    Glenn Dale, Maryland, 20769, United States

  • Site 85

    Norfolk, Virginia, 23502, United States

  • Site 86

    Coral Gables, Florida, 33134, United States

  • Site 87

    Rockville, Maryland, 20850, United States

  • Site 88

    San Antonio, Texas, 78218, United States

  • Site 89

    Birmingham, Alabama, 35244, United States

  • Site 90

    Sandy Springs, Georgia, 30328, United States

  • Site 91

    Sugarland, Texas, 77479, United States

  • Site 92

    Huntersville, North Carolina, 28078, United States

  • Site 93

    Northridge, California, 91324, United States

  • Site 94

    Thousand Oaks, California, 91320, United States

  • Site 95

    Hermitage, Tennessee, 37076, United States

  • Site 96

    Tamarac, Florida, 33321, United States

  • Site 99

    Miami, Florida, 33173, United States

Conditions

Explore the condition pages connected to this study.